Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision
Previous revision
rapamycin [2019/07/29 15:36] – [Collaborators] adminrapamycin [2019/07/29 18:46] (current) – [DNA methylation analysis] admin
Line 1: Line 1:
 ====== Rapamycin effects on aging-associated pathologies ====== ====== Rapamycin effects on aging-associated pathologies ======
 +
  
 ===== Objectives ===== ===== Objectives =====
  
-[[https://en.wikipedia.org/wiki/Sirolimus|Rapamycin]] is an inhibitor of the [[https://en.wikipedia.org/wiki/MTOR|mTOR]] pathway, which has been used in preventing rejection of solid organ allografts. In this multi-PI study on an older age healthy human cohort, we assess the usability and efficacy of Rapamycin in improving physical performance, cardiac and vascular health, and immune outcomes. This approach is motivated by the promising results that were observed in prior studies on mice models. Oncinfo contributes in this study through analysis of gene expression and DNA methylation profiles. +[[https://en.wikipedia.org/wiki/Sirolimus|Rapamycin]] is an inhibitor of the [[https://en.wikipedia.org/wiki/MTOR|mTOR]] pathway and it has been used in preventing rejection of solid organ allografts. In this multi-PI study on an older age healthy human cohort, we assess the usability and efficacy of Rapamycin in improving physical performance, cardiac and vascular health, and immune outcomes. This approach is motivated by the promising results that were observed in prior studies on mice models. Oncinfo contributes in this study through analysis of gene expression and DNA methylation profiles.
  
 ===== Data ===== ===== Data =====
  
-  - DNa methylation data of+  - DNA methylation data of {{:wiki:public:plan_discussed_with_habil_07_24_19.docx|29 subjects}}  were measured in 2019 using Infinium [[https://support.illumina.com/downloads/infinium-methylationepic-v1-0-product-files.html|MethylationEpic]] V1 Array. PBMC samples were collected before and after Rapamycin (16 subjects) and placebo (13 subjects) treatment for 6-8 weeks.
  
  
 ===== Collaborators ===== ===== Collaborators =====
  
-Dr. [[https://wp.uthscsa.edu/mimg/team-member/ellen-kraig-ph-d/|Ellen Kraig]], an immunologist from the University of Texas Health Science Center at San Antonio.+Dr. [[https://wp.uthscsa.edu/mimg/team-member/ellen-kraig-ph-d/|Ellen Kraig]], an immunologist, and Dr. [[https://www.uthscsa.edu/academics/biomedical-sciences/faculty/profile/0V71EU5IM/Kellogg,-Dean-L.-Jr.|Dean Kellogg]], a physiologist, both from the University of Texas Health Science Center at San Antonio
 + 
 + 
 +===== DNA methylation analysis ===== 
 + 
 +We follow the Bioconductor [[https://www.bioconductor.org/packages/release/workflows/vignettes/methylationArrayAnalysis/inst/doc/methylationArrayAnalysis.html#differential-methylation-analysis|workflow]] to identify the probes and regions that are differentially methylation due to Rapamycin treatment.
  
  
 ===== Related work ===== ===== Related work =====
 +
 +  - Kraig, Ellen, et al. "A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects." [[https://www.sciencedirect.com/science/article/pii/S0531556517309130|Experimental gerontology]] 105 (2018): 53-69.